Daily FNArena News - Australia
All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | Technicals | Treasure ChestPrevious Stories
NRW Holdings Diversifies Growth Options
Dec 03 2019
BGC Contracting is highly complementary to the NRW Holdings maintenance business but, as this is the company’s largest acquisition to date, it is not without risks.
CSL Reaping The Reward Of Foresight
Dec 02 2019
CSL has shown foresight in expanding plasma collection over recent years, enabling significant share in a market where demand for immunoglobulin has run ahead of supply.
FNArena Corporate Results Monitor – 02-12-2019
Dec 02 2019
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.
Fisher & Paykel Healthcare Too Pricey?
Nov 29 2019
Fisher & Paykel Healthcare experienced a jump in device sales during the first half but brokers remain concerned about the high price of the stock.
Australian Sales Drag On Harvey Norman
Nov 28 2019
Australian sales remain the critical weak spot for Harvey Norman in the lead up to the festive season as the retailer’s key categories face a tough consumer environment.
Risky Move For Evolution Mining
Nov 27 2019
Evolution Mining has embarked on its riskiest acquisition to date, the Red Lake gold mine in Canada.
Brokers Welcome Caltex Plans For Retail IPO
Nov 26 2019
Brokers welcome the potential for a future capital return as Caltex announces plans to spin off an interest in most of its freehold retail property.
Bank Of Queensland Recovery Likely Long-Dated
Nov 26 2019
Bank of Queensland may have announced a capital raising to shore up its balance sheet and provide the flexibility to improve operations but brokers are not that impressed.
Metcash Under Scrutiny After Losing 7-Eleven
Nov 25 2019
Grocery wholesaler Metcash has lost its second major contract in 18 months, exacerbating speculation around the scale and sustainability of the company’s distribution channel.
Mayne Pharma Aspires To Specialisation
Nov 25 2019
Mayne Pharma aspires to have more than 60% of its FY24 revenue from US specialty products, although significant challenges in generics are likely to beset the business in the interim.
Analyse The Market From A Different Angle
Latest News
| 1 |
TechnologyOne’s SaaS Transformation ‘Complete’Oct 07 2025 - Australia |
| 2 |
Stock Market in September RepublishOct 06 2025 - International |
| 3 |
Stock Market in SeptemberOct 06 2025 - International |
| 4 |
TechnologyOne Story by NoviOct 06 2025 - International |
| 5 |
Geopolitical Hedging Drives Investor Confidence in CommBankJun 12 2025 - General |